Anti-DLL3 antibody drug conjugates for treating cancer
AssigneesAbbvie Stemcentrx LLC, MedImmune, LLC
InventorsMichael Torgov, Philip Wilson Howard
Life of this patent
Estimating the term…
Abstract
Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.
Claims30
A method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an antibody drug conjugate (ADC) comprising an anti-DLL3 antibody covalently linked through a linker to one or more pyrrolobenzodiazepines (PBDs), wherein the one or more PBDs is/are:
A method of reducing the frequency of tumor initiating cells in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an antibody drug conjugate (ADC) comprising an anti-DLL3 antibody covalently linked through a linker to one or more pyrrolobenzodiazepines (PBDs), wherein the one or more PBDs is/are:
A method of sensitizing a tumor in a subject for treatment with an anti-cancer agent, to said subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an antibody drug conjugate (ADC) comprising an anti-DLL3 antibody covalently linked through a linker to one or more pyrrolobenzodiazepines (PBDs), wherein the one or more PBDs is/are:
A method of inhibiting metastasis in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an antibody drug conjugate (ADC) comprising an anti-DLL3 antibody covalently linked through a linker to one or more pyrrolobenzodiazepines (PBDs), wherein the one or more PBDs is/are:
A method of performing maintenance therapy to reduce cancer recurrence in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an antibody drug conjugate (ADC) comprising an anti-DLL3 antibody covalently linked through a linker to one or more pyrrolobenzodiazepines (PBDs), wherein the one or more PBDs is/are:
A method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an antibody drug conjugate (ADC) comprising:
- wherein Ab comprises an anti-DLL3 antibody.
A method of treating lung cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an antibody drug conjugate (ADC) comprising an anti-DLL3 antibody covalently linked through a linker to one or more pyrrolobenzodiazepines (PBDs),
- wherein the anti-DLL3 antibody comprises a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO:
- 405 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO:
- 407;
- wherein the one or more PBDs is/are:
- and
- wherein the pharmaceutical composition comprises a DAR of 2+/−0.4.
A method of treating lung cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an antibody drug conjugate (ADC) comprising:
- wherein Ab comprises an anti-DLL3 antibody comprising a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO:
- 405 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO:
- 407;
- and
- wherein the pharmaceutical composition comprises a DAR of 2+/−0.4.
Dependencies are inferred from the claim text.